MASSDEVICE ON CALL — Sanofi’s (NYSE:SNY) iPhone glucose meter, the iBGStar, landed 510(k) clearance from the FDA, making it the first iPhone glucose meter to win a nod from the federal watchdog agency.
The company’s website describes the meter as "is the first available blood glucose meter that seamlessly connects to the Apple iPhone and iPod touch for the flexibility to manage your diabetes whenever, wherever."
Sanofi’s device, which connects the AgaMatrix glucose monitoring technology to iPhones and iPods, won CE Mark clearance earlier this year.
Sign up to get our free newsletters delivered straight to your inbox
"The iBGStar is just one component in what will be series of devices from Sanofi, all of which will be interconnected and push the company closer to their quest to handle everything a patient needs, soup-to-nuts," reported the Diabetic Investor.
The companion app to the iBGStar is not yet available in the iPhone AppStore.
Neoprobe Corp. gets a name change
Neoprobe Corp. will change its name and stock symbol on January 5, 2012, according to a press release. The company will rebrand to Navidea Biopharmaceuticals Inc. and begin trading under the NAVB ticker.
Berwick on his time in the CMS corner office
Former administrator of the Centers for Medicare and Medicaid Services Donald Berwick spoke to the New York Times about his short, 17-month tenure, health care reform and the Obama administration.
Reusing pacemakers from dead patients is safe
A study published in the American Journal of Cardiology found that removing pacemakers from deceased Americans, sterilizing them and implanting them in Indian patients is "very safe and effective," according to a press release.
Osteoporosis drugs prolong life of joint implants
Patients not prescribed osteoporosis drugs after joint replacement surgery were twice as likely to need revision procedures within five years when compared to patients who received the drugs, according to MedPageToday.com.
S3V builds new R&D facility
Bangalore, India-based S3V Vascular Technologies will establish a manufacturing and development facility for products in intervention cardiology, neurology, peripheral and endovascular treatments, reported BusinessReviewIndia.in.
Titan’s surgery bots get a test run
Titan Medical Inc. signed a non-binding memorandum of understanding with Chennai, India-based Apollo Hospitals Enterprise to test and evaluate the company’s Amadeaus robotic surgical technologies, according to a press release.
